Breaking RepliCel (OTCQB:
$REPCF; TSX: $RP.V) @RepliCel News; US Patent Issued to for its Novel
Dermal Injection Technologies
With exclusive U.S. rights to RCI-02 patents,
RepliCel edges its nearest-term commercial asset closer to launch in large
aesthetic market
VANCOUVER, BC – April 25, 2017 - (Investorideas.com Newswire) RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV:RP) (FRA:P6P2)
(“RepliCel” or the “Company”), a clinical stage regenerative medicine company
developing cell therapies for aesthetic and orthopedic conditions, today
announced the granting of a key
patent in the United States (U.S. Patent No. 9,616,182) covering significant
components of the Company’s novel,
multi-needle dermal injection device.
No comments:
Post a Comment